Compare Caesars Entertainment Inc (CZR) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance

Caesars Entertainment (CZR) trades at $29.62, down 1.5% on the day, with a bearish technical signal and recent quarterly earnings misses. The company reported a Q2 2026 loss of $0.30 per share, missing estimates, but revenue of $3.0 billion topped expectations. Fundamentals show a negative net income margin of -3.99% and high long-term debt of $12.03 billion, though operating cash flow remains strong at $1.30 billion in 2025. The pending acquisition by Tilman Fertitta for approximately $17.6 billion is a key development, as reported by the Wall Street Journal on July 28, 2026.

CZR presents a mixed outlook with acquisition potential offset by persistent losses and debt. The stock's low P/S ratio of 0.52 offers value, but investors face risks from earnings volatility and competitive pressures in the leisure sector. Analyst sentiment is cautious with 70% hold ratings, reflecting uncertainty around profitability improvements and integration post-acquisition.

Zimmer Biomet (ZBH) trades at $97.9, up 0.12% on the day, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $2.07, beating estimates, and raised its 2026 outlook. Revenue growth remains steady, supported by hips, specialty businesses, and technology. Key financials show a P/E of 23.6 and net income margin of 9.48%, while cash flow from operations improved to $1.70B in 2025.

The outlook is positive, with a consensus price target of $103.56 offering ~6% upside. Risks include competitive pressures and margin volatility, but consistent earnings beats and institutional accumulation support a constructive view for long-term investors.